• Mashup Score: 26

    This phase 2 nonrandomized clinical trial evaluates the deep response rate and tolerability of neoadjuvant nivolumab plus chemotherapy followed by response-stratified chemoradiation therapy in nonvirally mediated stage IVa/b head and neck squamous cell carcinoma.

    Tweet Tweets with this article
    • Neoadjuvant nivolumab + chemotherapy followed by response-stratified chemoradiation in stage IVa/b nonvirally mediated head & neck cancer showed favorable survival & less toxic effects among responders receiving response-adapted chemoradiation. https://t.co/9cQBKoJbP9

  • Mashup Score: 32

    This cohort study examines the harms and benefits of regimens containing immune checkpoint inhibitors in individuals with non–small cell lung cancer.

    Tweet Tweets with this article
    • Most viewed this week from @JAMAOnc: Combining immune checkpoint inhibitors with chemotherapy in the first line of treatment for older adults with non–small cell lung cancer can delay mortality but increases the risk of severe adverse events. https://t.co/KYKx3picR3 https://t.co/OnMt8iSrqb